Journal of Medical Society

LETTER TO EDITOR
Year
: 2017  |  Volume : 31  |  Issue : 1  |  Page : 65-

Triple-negative breast cancer: Positive factors


Rashmi Patnayak1, Amitabh Jena2,  
1 Department of Pathology, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India
2 Department of Surgical Oncology, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India

Correspondence Address:
Amitabh Jena
Department of Surgical Oncology, Sri Venkateswara Institute of Medical Sciences, Tirupati - 517 507, Andhra Pradesh
India




How to cite this article:
Patnayak R, Jena A. Triple-negative breast cancer: Positive factors.J Med Soc 2017;31:65-65


How to cite this URL:
Patnayak R, Jena A. Triple-negative breast cancer: Positive factors. J Med Soc [serial online] 2017 [cited 2022 Jan 27 ];31:65-65
Available from: https://www.jmedsoc.org/text.asp?2017/31/1/65/198472


Full Text

Dear Editor,

In India, the toll of death due to breast cancer is rising. A routine work-up for breast carcinoma includes evaluation of estrogen receptors, progesterone receptor, and human epidermal growth factor receptor-2/neu status for therapeutic consideration. Triple-negative cancers are those which are negative for the above-mentioned markers and hence do not respond to standard therapy. They are aggressive and tend to affect younger women <40 years. In a previous study, we found 22.7% cases to be triple negative. [1] Another study from Sharma et al. found 31.9% triple-negative breast cancers. [2] As mentioned in the editorial "What's positive about triple-negative breast cancers?" new therapeutic models are being tried for these subset of breast cancers. [3] Androgen receptor evaluation is one such method. Recently, we analyzed our data and found 20% triple-negative breast cancers showing positivity for androgen receptor [unpublished data]. We agree with the observation that androgen receptor has a crucial role to play in triple- negative breast cancers. The future for androgen receptor does hold promise as illustrated by the recent trials. [4]

Data from various centers of our country coupled with follow-up information will be valuable in determining the prognosis and in providing a targeted therapy for triple-negative breast cancer patients.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

1Patnayak R, Jena A, Rukmangadha N, Chowhan AK, Sambasivaiah K, Phaneendra BV, et al. Hormone receptor status (estrogen receptor, progesterone receptor), human epidermal growth factor-2 and p53 in South Indian breast cancer patients: A tertiary care center experience. Indian J Med Paediatr Oncol 2015;36:117-22.
2Sharma M, Sharma JD, Sarma A, Ahmed S, Kataki AC, Saxena R, et al. Triple negative breast cancer in people of North East India: Critical insights gained at a regional cancer centre. Asian Pac J Cancer Prev 2014;15:4507-11.
3Laishram RS, Singh NS. What's positive about triple negative breast cancers? J Med Soc 2015;29:61-3.
4Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 2013;19:5505-12.